The exit meeting marks the official conclusion of a GMP inspection. During this meeting, inspectors present their findings and assess any potential non-conformities. Thorough preparation helps companies to correctly interpret the observations and implement necessary measures at an early stage.

Why the exit meeting is important in GMP inspections

The exit meeting is the final official item on the agenda of a GMP inspection. Once inspectors have reviewed documents, toured production areas and conducted interviews, the key findings are summarised and presented to the company.

For pharmaceutical manufacturers, this meeting offers the opportunity to obtain initial assessments from the regulatory authority or the audit team. At the same time, the discussion serves to clarify any potential misunderstandings and answer outstanding questions. The findings of the exit meeting often form the basis for the subsequent GMP inspection report.

Particularly within the context of an effective quality management system, companies should carefully document and evaluate the issues raised during the meeting.

What topics are discussed during the exit meeting?

The focus is on the observations and potential non-conformities identified during the inspection. The inspectors explain their findings and classify them according to their significance for product quality and compliance with regulatory guidelines.

Topics such as GMP documentation, data integrity, equipment qualification or the implementation of CAPA measures are frequently addressed. Depending on the type of inspection, aspects of supplier qualification or risk management may also play a role.

It is important to note that the observations presented initially represent a preliminary assessment. The final classification is usually only provided in the official inspection report.

How should companies prepare?

Structured preparation contributes significantly to the success of the exit meeting. Responsibilities should be clearly defined and relevant contact persons identified before the inspection begins.

During the inspection, it is advisable to document all the inspectors’ questions and findings on an ongoing basis. This enables potential points of criticism to be analysed at an early stage and initial corrective actions to be prepared in order to ensure Good Manufacturing Practice.

Representatives from the quality assurance and production departments should also attend the exit meeting. This allows technical questions to be answered directly and necessary follow-up measures to be coordinated.

What significance do the results have for ongoing compliance?

The results presented at the exit meeting are of great significance for ongoing cooperation with the regulatory authorities. Companies gain an initial overview of which measures may be required following the inspection.

If non-conformities are identified, these must be systematically assessed and addressed through appropriate CAPA processes. Transparent documentation of the measures taken supports the demonstration of sustainable improvement and strengthens compliance with regulatory guidelines.

Furthermore, exit meetings provide valuable insights into the continuous optimisation of the pharmaceutical quality system. Companies can use the insights gained to improve processes and prepare for future GMP inspections more efficiently.

Professional pharmaceutical translations and experienced pharmaceutical interpreters can make a significant contribution, particularly during international GMP inspections. They facilitate precise communication between companies, auditors and regulatory authorities and help to avoid misunderstandings during critical discussions. This enables inspection procedures to be organised more efficiently and regulatory requirements to be communicated reliably.

Image: Europeana, unsplash.com